Animals were divided into five groups (n = 10). Control (C), sodium tungstate-treated control (TC), streptozotocin-induced diabetic (D), streptozotocin-induced diabetic rats were treated by sodium tungstate form 1 week before streptozotocin (STZ) injection (TD1), and diabetic rats treated with sodium tungstate 1 week after STZ administration (TD2). The histopathologic changes in pancreas were investigated by light microscopy. Body weight, blood glucose, insulin levels, food intake and fluid intake were compared between groups. Serum insulin levels were determined by ultra-sensitive rat insulin kit, using double-antibody ELISA.
Group D and TD2 showed significant weight loss, polydipsia, polyuria and polyphagia compared to groups C and TC (p < 0.01). TD1 group protects diabetic-induced rats from elevation of glucose compared to groups D and TD2 (p < 0.01). Group TD1 showed significant decrease in fasting glucose levels and oral glucose tolerance test in comparison to groups D and TD2 (p < 0.01). Microscopic evaluation of pancreas showed that in TD1 group, tungstate protects STZ-induced beta-cells degenerations.
Pre-treatment with sodium tungstate leads to amelioration of diabetic complications and short-term pre-treatment with tungstate can converts the diabetic state by sustaining a few, although it is critical, amount of beta-cells that adequately maintain normoglycemia.